Please login to the form below

bosentan

This page shows the latest bosentan news and features for those working in and with pharma, biotech and healthcare.

J&J agrees $30bn deal to acquire Actelion

Meanwhile, J&J claims the company's marketed products including its trio of pulmonary artery hypertension (PAH) drugs, including Tracleer (bosentan) - now facing generic competition - as well as follow-up drugs

Latest news

Actelion reports late-stage trial failure as J&J talks continue

Tracleer (bosentan) which has lost patent protection in the US and Europe.
J&J back in frame to buy Actelion after Sanofi talks break down

Actelion has been through a difficult patch after losing patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), but is on the up with strong growth for follow-up PAH
J&J abandons talks with Actelion as another suitor circles

After a challenging couple of years following the loss of patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), Actelion is now riding high on the back of strong growth
Resurgent Actelion catches J&J's eye

Actelion's top-selling product Tracleer (bosentan) has already lost patent protection in some markets and saw sales slide 15% in the first nine months of the year to CHF 790m (
Actelion gets EU go-ahead for Uptravi in PAH

Tracleer (bosentan).

More from news
Approximately 4 fully matching, plus 22 partially matching documents found.

Latest appointments

J&J's Jane Griffiths named global head of Actelion

At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).
New associate director at Packer Forbes

Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Editorial Director – Medical Education – Oxford: Negotiable

Scientific Director: Great salary and bebefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editor – Medical Education Agency – Bucks: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and bebefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Programme Executive: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer: Great salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...